Burning Rock Biotech (BNR) Cash & Equivalents (2019 - 2026)

Burning Rock Biotech (BNR) has reported Cash & Equivalents for 8 consecutive years, with $65.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 4.66% year-over-year to $65.1 million; the TTM figure through Mar 2026 stood at $65.1 million (down 4.66% YoY), while the FY2025 annual figure was $68.8 million, down 3.83% from the prior year.
• Cash & Equivalents came in at $65.1 million for Q1 2026 at Burning Rock Biotech, down from $67.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $199.7 million in Q1 2022, with the low at $63.5 million in Q2 2025.
• Average Cash & Equivalents over 5 years is $97.4 million, with a median of $79.3 million recorded in 2024.
• Across the five-year window, Cash & Equivalents plunged 44.32% in 2022 and fell 4.66% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $127.3 million in 2022, then sank by 32.9% to $85.4 million in 2023, then slipped by 15.29% to $72.4 million in 2024, then dropped by 6.8% to $67.4 million in 2025, then declined by 3.55% to $65.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $65.1 million, $67.4 million, and $65.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.